MiNK Therapeutics (INKT) Convertible Debt (2020)
MiNK Therapeutics (INKT) posted Convertible Debt of $43.8 million for Q4 2020.
MiNK Therapeutics (INKT) Convertible Debt (2020) Analysis & Trends
MiNK Therapeutics has reported Convertible Debt for 1 years, with the latest figure at $43.8 million in Q4 2020.
- Quarterly Convertible Debt changed N/A year-over-year to $43.8 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $43.8 million (changed N/A YoY) and the FY2020 annual result came in at $43.8 million, changed N/A from the prior year.
- Convertible Debt was little changed at $43.8 million in Q4 2020 per INKT's latest filing.
- Over five years, Convertible Debt peaked at $43.8 million in Q4 2020 and troughed at $43.8 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - |
| 10 | MiNK Therapeutics | 58.47 Mn | 58.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 43.82 Mn |